# A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines

> **NCT06946160** · PHASE3 · COMPLETED · sponsor: **Espad Pharmed** · enrollment: 146 (actual)

## Conditions studied

- Glabellar Lines
- Glabellar Frown Lines

## Interventions

- **DRUG:** Abobotulinumtoxin A (Espad Pharmed Darou Co.)
- **DRUG:** Abobotulinumtoxin A (Ipsen Co.)

## Key facts

- **NCT ID:** NCT06946160
- **Lead sponsor:** Espad Pharmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-28
- **Primary completion:** 2025-02-18
- **Final completion:** 2025-02-18
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06946160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06946160, "A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06946160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*